NasdaqGS:KURABiotechs
Kura Oncology (KURA) Q1 Loss Of US$73 Million Reinforces Bearish Profitability Concerns
Kura Oncology (KURA) opened Q1 2026 with revenue of US$18.3 million and a basic EPS loss of US$0.83, while trailing 12 month figures show revenue of US$71.6 million and a basic EPS loss of US$3.35. Over recent quarters, the company has seen quarterly revenue move between US$14.1 million and US$20.8 million, with basic EPS losses in a range from US$0.66 to US$0.92. Investors are likely to weigh this latest print against expectations for faster top line growth relative to ongoing pressure on...